The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or ...

Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements. | ...

Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed ...

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...

-- Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGene -- IFLI contributed up to $9 million to Enterome's private funding round in 2025 -- Enterome has announced a ...

Curcumin and milk thistle extracts reduce oxidative stress, enhance vaccine response and support intestinal integrity in ...

Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) ...

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel ...

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...